INSR and metabolic syndrome: It has previously been shown that patients with INSR mutations, despite severe insulin resistance, do not show fatty liver, dyslipidemia, or suppressed plasma adiponectin, while patients from the single family described to date with severe insulin resistance ascribed to an AKT2 mutation exhibit all these to a severe degree (9).